ATRYS HEALTH

Trading sesion


17/07/2018 Close

3.0400

Last price


62.11 mill. €

Capitalisation

-0.65

Dif.(%)


52.00

% Year 2018

Last Trade

Date

17/07/2018

Last

3.0400

Ref.

3.0600

Dif.(%)

-0.65

Volume (Shares)

7,598

Turnover (€x1000)

23.10

Security

Security name

ATRYS HEALTH

Ticker

ATRY

ISIN

ES0105148003

NIF

A-84942150

Shares Admitted

20.430.329

Nominal

0,01 Euros

Capital Admitted

204.303,29 Euros

Trading

Continuo

Liquidity Provider

GVC Gaesco Beka, S.V., S.A.

Registered Advisor

NORGESTIÓN, S.A.

Auditor

BDO AUDITORES, S.L.

Address

CL/ VELAZQUEZ 24, 28001 MADRID

Contact

relacioninversores@atryshealth.com

Historical Summary

 201620172018 until 17/07

Capital Admitted (thousands of euros)

112112204

Shares (x 1,000)

11,15311,15320,430

Period Close Price (euros)

1.48002.15003.0400

Period Last Price (euros)

1.48002.15003.0800

Period High Price (euros)

1.84002.15003.3200

Period Low Price (euros)

1.40001.39001.8600

Capitalisation (thousands of euros)

16,50723,97962,108

Volume (thousands of shares)

2607722,057

Turnover (thousands of euros)

3931,0715,402

"ATRYS Health specializes in innovative medical diagnostic imaging.and personalized cancer diagnosis and treatments in advanced single-dose radiation therapy company. Our commitment to R & D puts us at the forefront of individualized medicine ."

 

Company Profile

ATRYS is an innovative company dedicated to providing diagnostic services and medical treatments of excellence, combining technical diagnostic accuracy in pathological and molecular and diagnostic anatomy online image through its own technological platform multi-specialty, with new radiation oncology treatments. 

ATRYS aims to apply the most advanced methods of diagnosis and treatment of cancer. The commitment of the Company is to bring medical excellence as many potential patients, by applying the latest technology and the most advanced scientific knowledge. 

The company also offers online services in different specialties medical imaging diagnosis, through its own platform, such as radiology, cardiology, ophthalmology and dermatology. These services allow relocate the report of the specialist center where the test is performed. 

ATRYS  carries out an integrated management of oncological disease, from individualized diagnosis (pathology, molecular, genetic and radiological) to the hypo-fractionated radiotherapy or single dose patients likely to benefit from this treatment, through collaborative arrangements management centers reference health. 

The company, whose headquarter is located in Madrid, has two main laboratories, equipped with equipment and technologies needed for diagnosis and research, located in Barcelona and Granada Genyo Center. 

Also, ATRYS develops projects of applied R & D that have generated several patent families, in collaboration with centers of national and international reference, aimed at improving diagnostic systems and treatment modalities, which allows the company to incorporate latest scientific advances to their clinical practice. 

The ATRYS business model is based on four pillars: 

  • Services of imaging diagnostic medical  excellence multi-specialty online, for public and private health centers both Spanish and international. 

  • Oncological diagnosis personalized services, including the specialties of pathology, molecular pathology and genetics, incorporating the latest scientific advances. 

  • Advanced radiation oncology services to provide customized radiation treatments Single Dose in collaboration with private and public medical centers.

  • R & D and patents to develop tools to improve diagnosis and treatment.

Relevant Facts and Notices

Significant participations

Photo Gallery

To obtain detailed information or information in other formats, please contact BME Market Data at marketdata@grupobme.es or visit the website www.bmemarketdata.es.

The information provided by the different websites of Grupo BME is for internal use only. For any commercial use and/or other usage that involves the redistribution of the information to third parties, it is required a prior and express permission from BME Market Data. Please contact us at marketdata@grupobme.es.